KRAS-Mutant Pancreatic CancerPhase 1NCT07671339
ELI-002 7P + mFOLFIRINOX ± Tislelizumab
ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
What the film says
This trial is for resectable pancreatic cancer that has not spread, in adults.
The idea: add fostamatinib, a Syk kinase inhibitor currently FDA approved for ITP, to standard chemotherapy given before and after surgery. Patients take it by mouth twice a day for 7 days before chemotherapy, and then during chemotherapy. The main measure is whether surgery is delayed.
This phase 1b trial plans 36 patients. At the University of California, San Diego Moores Cancer Center, Andrew Lowy, listed as study chair, leads it.
Public record; not medical advice.
Sources behind this film
Resectable pancreatic cancer that has not spread, adults; Fostamatinib, a Syk kinase inhibitor currently FDA approved for ITP, added to standard chemotherapy before and after surgery; By mouth twice a day for 7 days before chemotherapy, then during chemotherapy; Main measure is whether surgery is delayed (+2 more lines)
The drug
Fostamatinib is a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura but it has not been studied in PDAC. The investigators hypothesize that Syk inhibition reprograms macrophages to an immunostimulatory phenotype in the tumor microenvironment. Thus, Syk inhibition with fostamatinib in combination with chemotherapy could improve outcomes for patients with PDAC while having a favorable safety profile.
Although immune checkpoint inhibition has transformed the treatment of some solid malignancies, it has made minimal impact in pancreatic ductal adenocarcinoma (PDAC), which is characterized by a profoundly immunosuppressive microenvironment.
Recent published work by the study investigators demonstrated that inhibition of the Syk kinase - alone and in combination with gemcitabine - in preclinical models of PDAC (animal tumor models and human tissues) reprogrammed tumor associated macrophages resulting in enhanced anti-tumor immunity. With this phase Ib study, the investigators aim to expand the preclinical findings to patients with PDAC.
The study
This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non metastatic pancreatic ductal adenocarcinoma (PDAC).
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.